News Release

Patients with inflammation more likely to develop diabetes after transplant

Peer-Reviewed Publication

Thomas Jefferson University

(PHILADELPHIA) - Up to 30 percent of people who receive organ transplants will develop diabetes, but researchers are unsure why. Although doctors typically blame immunosuppressive drugs that transplant recipients take to prevent organ rejection, it's unclear why some people develop the lifelong disorder, while others do not. A new study in kidney transplant recipients suggests that patients with more inflammation prior to surgery are more likely to develop diabetes than those with less overall inflammation, and that a patient's fat stores also play a role. The research, published in the journal CardioRenal Medicine, suggests there may be opportunities for intervention and reducing the rate of diabetes in kidney recipients.

"For patients who have received a new lease on life from a donated kidney, developing diabetes can be a major blow," says first author on the study Maria Martinez Cantarin, M.D. an Assistant Professor in the Division of Nephrology at the Sidney Kimmel Medical College at Thomas Jefferson University. "We hadn't had a good sense of how diabetes could be avoided for these patients."

To get a better sense of the disease process that leads to diabetes in transplant recipients, Dr. Martinez Cantarin and colleagues took blood and tissue samples from 32 kidney recipients and, for comparison, 36 kidney donors. Of the 32 kidney recipients, 11 went on to develop diabetes within one year of follow up.

When the researchers compared levels of a chemical that instigates inflammation, called tumor necrosis factor alpha, or TNF-alpha, they saw that patients who developed diabetes had higher levels of this chemical in their blood before their surgery than those who didn't develop diabetes, after taking into account other known factors influencing diabetes risk. In fact, for every 25 percent increase in TNF-alpha over the comparison group, the patients doubled their risk of developing diabetes.

The researchers also looked at the patients' fat tissue. "Patients on dialysis, who eventually end up needing new kidneys, typically lose weight. So we tend to think of a little extra fat as a good thing. Heavier patients do better," says Dr. Martinez Cantarin. However, when the researchers sampled fat tissue from the kidney transplant recipients and donors, the ones who developed diabetes had 40 percent higher production of TNF-alpha than those who didn't. This suggests that in some patients whose fat produced high levels of inflammatory chemicals, the fat was not protective and instead increased their chances of developing diabetes.

"The finding is important because it changes our focus as clinicians. Before, diabetes seemed like an inevitable side effect of the transplantation process," said Martinez Cantarin. "This study points to the idea that we may be able help the patient alter or control inflammation prior to transplantation in order to reduce the risk of developing diabetes," said Martinez Cantarin.


This work was supported in part by NIH grants T32GM008562 and ADA grants 7-12-JF-41. The authors have no conflicts of interest to disclose.

Article Reference: MP Martinez Cantarin et al., "Association of inflammation prior to kidney transplantation with post-transplant diabetes mellitus," CardioRenal Medicine, DOI:10.1159/000446294, 2016.

For more information contact Edyta Zielinska, 215-955-5291, or Gail Benner, 215-955-2240,

About Jefferson

Our newly formed organization, Jefferson, encompasses Thomas Jefferson University and Jefferson Health, representing our academic and clinical entities. Together, the people of Jefferson, 19,000 strong, provide the highest-quality, compassionate clinical care for patients, educate the health professionals of tomorrow, and discover new treatments and therapies that will define the future of health care.

Jefferson Health comprises five hospitals, 17 outpatient and urgent care locations, as well as physician practices and everywhere we deliver care throughout the city and suburbs across Philadelphia, Montgomery and Bucks Counties in Pa., and Camden County in New Jersey. Together, these facilities serve nearly 73,000 inpatients, 239,000 emergency patients and 1.7 million outpatient visits annually. Thomas Jefferson University Hospital is the largest freestanding academic medical center in Philadelphia. Abington Hospital is the largest community teaching hospital in Montgomery or Bucks counties. Other hospitals include Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; and Abington-Lansdale Hospital in Hatfield Township.

Thomas Jefferson University enrolls more than 3,800 future physicians, scientists, nurses and healthcare professionals in the Sidney Kimmel Medical College (SKMC), Jefferson Colleges of Biomedical Sciences, Health Professions, Nursing, Pharmacy, Population Health and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center.

For more information and a complete listing of Jefferson services and locations, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.